Navigation Links
AFFiRiS AG: Capital Increase: AFFiRiS Brings Santo VC and MIG 11 on Board
Date:11/8/2011

active markets. We are delighted to offer our investors another opportunity to invest in AFFiRiS through this capital increase."

If the ongoing projects develop as expected, the mutually agreed option for Santo and MIG could deliver another EUR 30 million in equity to the company.

About AFFiRiS AG (as of November 2011):

Based on the company's own patent positions, AFFiRiS develops tailor-made peptide vaccines for Alzheimer's disease, Atherosclerosis, Parkinson's disease, hypertension and several other conditions with urgent requirement for new treatments and attractive market volumes. Alzheimer's is the current lead indication. A license and option agreement for the Alzheimer's vaccine programme was concluded with GlaxoSmithKline in October 2008, triggering an up-front payment of EUR 22.5 million. The contract envisages (milestone-dependent) payments of up to EUR 430 million. An initial milestone payment of EUR 10 million was made in October 2009 followed by EUR 3.5 million as announced recently. AFFiRiS currently employs 83 highly-qualified staff at the Campus Vienna Biocenter in Vienna, Austria (http://www.affiris.com).

About Santo VC GmbH

Santo VC GmbH is the venture capital arm of Athos Service GmbH, the family office of the Strüngmann family.

MIG Funds

Based in Munich, MIG Funds ranks as one of Germany's most dynamic venture capital companies. Since 2005 MIG has been launching funds and has invested in over 25 innovative German and Austrian companies to date.

The MIG fund portfolio is managed by MIG AG. With a total volume of over EUR 500 million, the funds are marketed exclusively by AWAG (http://www.awag.ag) and are primarily directed at private investors.

MIG funds are conceived and drawn up by HMW Emissionshaus AG.

For further information on MIG funds, MIG AG and its investment portfolio, pleas
'/>"/>

SOURCE AFFiRiS AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AFFiRiS - MIG-Fonds Increases Investment by Euro 3 Million
2. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
3. AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
4. AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS
5. AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimers Vaccine Candidate AD02 into Clinical Phase II Testing
6. AFFiRiS AG: Vaccination Against Hypertension is Development Project No. 4 and has Already Been Awarded an FFG Grant of up to EUR 1.2 Million
7. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
8. TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm
9. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
10. Sinobiomed Retains CB Capital Partners as Financial Advisor to Maximize Shareholder Value
11. Aegis Analytical Corp. Showcases Discoverant at Inaugural Venture Capital in the Rockies Fall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015   Cypher Genomics, Inc., the ... SQNM ), the leading molecular diagnostics ... generation noninvasive prenatal tests (NIPT). Through this agreement, ... Mantis™, to advance analysis of clinically-relevant fetal sub-chromosomal ...
(Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval application ... the use of Medtronic,s SynchroMed ® II implantable ... use with United Therapeutics, Remodulin ® (treprostinil) Injection ...
(Date:12/24/2014)... GMO corn cases filed across the United States, ... of being consolidated in a Kansas federal court for pretrial ... 162 Corn Litigation, MDL No. 2591 in the U.S. District ... Syngenta GMO corn multidistrict litigation (MDL) has been handed over ...
(Date:12/24/2014)... December 23, 2014 The report ... its definition, classification, application and industry overview. This ... product cost structure. Production is separated by regions, ... raw materials, equipment, downstream client survey, marketing channels, ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... somehow survived where other traditional marketing tools and old ... must face harsher realities once again, all to ensure ... Web sites are simply doomed. While billions of Web ... clash into the billions of surfing customers and simply ...
... Ted Kanavas, R-Brookfield, called on the Legislature and the ... Development Fund. , ,The fund would use existing information ... Administration and segregate a portion of the funds for ... would not flow into this fund. , ,This fund ...
... Corporation and First Data Corporation jointly ... provides for the purchase of substantially all of the ... approximately $610 million in cash. As the majority shareholder ... million and NYCE will become a Metavante subsidiary. , ...
Cached Biology Technology:The mysteries and the future of Web sites 2The mysteries and the future of Web sites 3The mysteries and the future of Web sites 4Metavante and First Data to buy PIN-debit company NYCE 2
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source ... launch of its new website design. "When we ... infancy", says Peter O,Neill , founder and CEO of ... industry needs involvement from the key players on a very ...
(Date:1/22/2015)... Conn. , Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: ... mobile commerce market, reports on the recent success of the Wocket™ smart ... Wocket smart wallet was named as one of the "11 ... the "5 Best Products Launched At CES So Far" by Newseveryday.com and ...
(Date:1/22/2015)...   EyeLock, Inc. , a market leader of iris-based identity ... to the new role of Senior Vice President of ... of mobile platforms and wearable solutions for EyeLock,s technologies. Gerber ... the semiconductor industry to his role at EyeLock, with expertise ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... Efforts to understand how the aging process affects the ... and older adults. "Everybody ages differently. By looking ... vascular health, we begin to understand that preventable factors ... State University psychology doctoral student Andrew Bender, lead author ...
... HOUSTON (May 8, 2012) The best doctors strive ... Rice University students to help him do so in the ... a prototype device to literally lift the weight from obese ... breathing. The respiratory assist device built by Team R-Aides ...
... the final stages of approving the use of the country,s ... guidance from scientists funded by PETA. The 3T3 Neutral Red ... when they come into contact with sunlight and is already ... scheduled to be accepted in China by late summer. Until ...
Cached Biology News:WSU researchers say genes and vascular risk modify effects of aging on brain and cognition 2WSU researchers say genes and vascular risk modify effects of aging on brain and cognition 3Rice students work on weighty problem for doctors 2Rice students work on weighty problem for doctors 3Rice students work on weighty problem for doctors 4
...
... atoms at the 3, 3', 4, and ... as an internal standard for the quantification ... PGE1 is the theoretical cyclooxygenase metabolite of ... undetectable in the plasma of normal humans ...
Acrylamide, 500 g. Assay: > 99.9%, acrylic acid: < 0.001%. Conductivity (35%): < 2 umhos/cm.Risks: 45, 46, 48, 23, 24, 25 ; Safety Precautions: 53, 44. Category: Nucleotides & Enzymes & Biochemicals...
Direct ELISA Assay Diluent, 10 L...
Biology Products: